Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain

CNS Neurol Disord Drug Targets. 2019;18(2):149-155. doi: 10.2174/1871527318666181128144343.

Abstract

Background & objective: The purpose of this study was to measure the effect on brain biomarkers after treatment with anticancer compounds - cytarabine (CT) and ferric carboxymaltose (FC) (Fe+3) in Wistar rats.

Methods: The Wistar rats were treated as follows: group 1 (control), NaCl 0.9%; group 2, CT (25 mg/k), group 3, FC(Fe+3) (50 mg/k) and group 4, CT + FC(Fe+3). The animals were sacrificed and their brains were obtained and used to measure lipoperoxidation (TBARS), H2O2, Na+, K+ ATPase, glutathione (GSH), serotonin metabolite (5-HIAA) and dopamine. The results indicated an enhancement of lipid peroxidation in the cortex and striatum of groups treated with FC(Fe+3) and CT, while GSH decreased in the cortex of group treated with CT + FC(Fe+3). Dopamine decreased in the cortex of the rats that received CT, while in the striatum, 5HIAA increased in all groups.

Results & conclusion: These results suggest that the treatment with CT and FC(Fe+3) boosted oxidative stress and led to an alteration in momoamine concentrations in the brain.

Keywords: Iron; anticancer agents; brain; malignant tumor; oncological diseases; oxidative damage..

MeSH terms

  • Animals
  • Brain / drug effects*
  • Brain / metabolism
  • Cytarabine / pharmacology*
  • Dopamine / metabolism
  • Ferric Compounds / pharmacology*
  • Hydrogen Peroxide / pharmacology
  • Lipid Peroxidation / drug effects*
  • Maltose / analogs & derivatives*
  • Maltose / pharmacology
  • Oxidation-Reduction / drug effects
  • Oxidative Stress / drug effects*
  • Rats, Wistar
  • Serotonin / metabolism

Substances

  • Ferric Compounds
  • Cytarabine
  • Serotonin
  • ferric carboxymaltose
  • Maltose
  • Hydrogen Peroxide
  • Dopamine